Form POS AM - Post-Effective amendments for registration statement:
SEC Accession No. 0001558370-25-003463
Filing Date
2025-03-21
Accepted
2025-03-21 16:07:23
Documents
75

Document Format Files

Seq Description Document Type Size
1 POS AM sngx-20241231xposam.htm   iXBRL POS AM 3390437
2 EX-21.1 sngx-20241231xex21d1.htm EX-21.1 13750
3 EX-23.1 sngx-20241231xex23d1.htm EX-23.1 5320
4 GRAPHIC sngx-20241231xposam001.jpg GRAPHIC 6870
5 GRAPHIC sngx-20241231xposam007.jpg GRAPHIC 784
6 GRAPHIC sngx-20241231xposam008.jpg GRAPHIC 796
7 GRAPHIC sngx-20241231xposam022.jpg GRAPHIC 3974
  Complete submission text file 0001558370-25-003463.txt   11220810

Data Files

Seq Description Document Type Size
8 EX-101.SCH sngx-20241231.xsd EX-101.SCH 66705
9 EX-101.CAL sngx-20241231_cal.xml EX-101.CAL 59289
10 EX-101.DEF sngx-20241231_def.xml EX-101.DEF 265384
11 EX-101.LAB sngx-20241231_lab.xml EX-101.LAB 556592
12 EX-101.PRE sngx-20241231_pre.xml EX-101.PRE 416690
78 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20241231xposam_htm.xml XML 1946478
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: POS AM | Act: 33 | File No.: 333-271049 | Film No.: 25760527
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)